Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ALB | P02768 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2284109 | 0.89 | LMNA (0.37) | LMNAALOX12ADRA1ASMN1; SMN2ALDH1A1 | |
| SCHEMBL2276807 | 0.88 | LMNA (0.34) | LMNAALOX12ADRA1ASMN1; SMN2ALDH1A1 | |
| SCHEMBL9368232 | 0.87 | LMNA (0.36) | LMNAALOX12ADRA1ASMN1; SMN2ALDH1A1 | |
| SCHEMBL9368222 | 0.87 | LMNA (0.36) | LMNAALOX12ADRA1ASMN1; SMN2ALDH1A1 | |
| SCHEMBL8476367 | 0.87 | LMNA (0.38) | LMNAALOX12ADRA1ASMN1; SMN2ALDH1A1 | |
| SCHEMBL8476369 | 0.87 | LMNA (0.38) | LMNAALOX12ADRA1ASMN1; SMN2ALDH1A1 | |
| SCHEMBL9372470 | 0.86 | LMNA (0.35) | LMNAALOX12ADRA1ASMN1; SMN2ALDH1A1 | |
| SCHEMBL9372482 | 0.86 | LMNA (0.35) | LMNAALOX12ADRA1ASMN1; SMN2ALDH1A1 | |
| SCHEMBL7866081 | 0.85 | LMNA (0.53) | LMNAALOX12ADRA1ASMN1; SMN2 | |
| SCHEMBL7866078 | 0.85 | LMNA (0.53) | LMNAALOX12ADRA1ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11649260-B2 | Functionalized N-acetylgalactosamine nucleosides | HONGENE BIOTECH CORPORATION (US) | 2023-05-16 | — | — | US | disclosed |
| US-20230034284-A1 | FUNCTIONALIZED N-ACETYLGALACTOSAMINE NUCLEOSIDES | HONGENE BIOTECH CORPORATION | 2023-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11649260-B2 | Functionalized N-acetylgalactosamine nucleosides | FUT6, B3GNT2, GALNT6 | LMNA 657/4885ALOX12 1988/4885ADRA1A 3290/4885 |
| US-20230034284-A1 | FUNCTIONALIZED N-ACETYLGALACTOSAMINE NUCLEOSIDES | FUT6, B3GNT2, GALNT6 | LMNA 657/4885ALOX12 1988/4885ADRA1A 3290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.